Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients
Open Access
- 20 October 2021
- journal article
- research article
- Published by Elsevier BV in EBioMedicine
- Vol. 73, 103626
- https://doi.org/10.1016/j.ebiom.2021.103626
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Introductions and early spread of SARS-CoV-2 in the New York City areaScience, 2020
- A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiologyNature Microbiology, 2020
- Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 VirusCell, 2020
- An In Vitro Microneutralization Assay for SARS‐CoV‐2 Serology and Drug ScreeningCurrent Protocols in Microbiology, 2020
- Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in MiceJournal of Virology, 2019
- Antibody-mediated protection against Ebola virusNature Immunology, 2018
- Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to ProtectionCell, 2018
- Nextstrain: real-time tracking of pathogen evolutionBioinformatics, 2018
- Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer ProtectionCell Host & Microbe, 2016
- CoronavirusesRNA Biology, 2011